Policy / Pricing A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma BioPharma DiveA series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.Policy / PricingRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health. Policy / PricingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Agios mulls early FDA filing for sickle cell therapyNext: FDA, after turbulent year, leaves drugmakers guessing on its direction Related Stories Policy / Pricing Decoding Medicare Advantage Coding Intensity pharminent July 1, 2026 Policy / Pricing UK partners with Eli Lilly on obesity plan pharminent June 29, 2026 Policy / Pricing EFPIA report adds to pressures on EU drug pricing policy pharminent June 24, 2026
